Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Treasury Shares (2016 - 2019)

Gyre Therapeutics (GYRE) has disclosed Treasury Shares for 8 consecutive years, with $1.6 million as the latest value for Q3 2019.

  • Quarterly Treasury Shares rose 19.01% to $1.6 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Sep 2019, up 19.01% year-over-year, with the annual reading at $821741.0 for FY2017, 482.84% up from the prior year.
  • Treasury Shares for Q3 2019 was $1.6 million at Gyre Therapeutics, down from $1.6 million in the prior quarter.
  • The five-year high for Treasury Shares was $1.6 million in Q2 2019, with the low at $44704.0 in Q1 2017.
  • Average Treasury Shares over 5 years is $920996.0, with a median of $1.0 million recorded in 2018.
  • The sharpest move saw Treasury Shares plummeted 79.89% in 2015, then skyrocketed 2195.98% in 2018.
  • Over 5 years, Treasury Shares stood at $103129.0 in 2015, then surged by 36.71% to $140990.0 in 2016, then surged by 482.84% to $821741.0 in 2017, then skyrocketed by 60.53% to $1.3 million in 2018, then increased by 19.01% to $1.6 million in 2019.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $1.6 million, $1.6 million, and $1.6 million for Q3 2019, Q2 2019, and Q1 2019 respectively.